Skip to main content
Erschienen in: Tumor Biology 6/2014

01.06.2014 | Research Article

MDM2 SNP309 variation increases cervical cancer risk among Asians

verfasst von: Xianlu Zhuo, Jie Ren, Dairong Li, Yongzhong Wu, Qi Zhou

Erschienen in: Tumor Biology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

MDM2 T309G polymorphism has been suggested to be a risk factor for a number of cancers. The association of MDM2 T309G genetic variation with cervical cancer risk remains inconclusive. In the present study, we aimed to get a more confidential result by conducting a quantitative meta-analysis. Relevant literature up to October 2013 was searched and screened. Essential information was rigorously extracted for data pooling and analyzing, and then, separate analyses on ethnicity and source of controls were also performed. As a result, four articles including five case–control studies were selected. The overall data failed to show a significant association between MDM2 T309G polymorphism and cervical cancer risk (GG vs TT: odds ratio (OR) = 1.31; 95 % confidence interval (CI) = 0.55–3.13; dominant model: OR = 1.22; 95 % CI = 0.65–2.31; recessive model: OR = 1.45; 95 % CI = 0.79–2.65). However, in the subgroup analysis about ethnicity, increased cancer risk could be shown among Asians (GG vs TT: OR = 2.15; 95 % CI = 1.03–4.51; recessive model: OR = 2.01; 95 % CI = 1.32–3.06). In conclusion, the results of the present study suggest that homozygous GG alleles of MDM2 T309G polymorphism might be a risk factor for cervical cancer among Asians. Further studies are needed get a more definitive conclusion.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
Zurück zum Zitat Wattleworth R. Human papillomavirus infection and the links to penile and cervical cancer. J Am Osteopath Assoc. 2011;111:S3–S10.PubMed Wattleworth R. Human papillomavirus infection and the links to penile and cervical cancer. J Am Osteopath Assoc. 2011;111:S3–S10.PubMed
3.
Zurück zum Zitat Gadducci A, Barsotti C, Cosio S, Domenici L, Riccardo Genazzani A. Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2011;27:597–604.CrossRef Gadducci A, Barsotti C, Cosio S, Domenici L, Riccardo Genazzani A. Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2011;27:597–604.CrossRef
5.
Zurück zum Zitat Li Q, Lozano G. Molecular pathways: targeting mdm2 and mdm4 in cancer therapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19:34–41.CrossRef Li Q, Lozano G. Molecular pathways: targeting mdm2 and mdm4 in cancer therapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19:34–41.CrossRef
6.
Zurück zum Zitat Qin JJ, Nag S, Voruganti S, Wang W, Zhang R. Natural product mdm2 inhibitors: anticancer activity and mechanisms of action. Curr Med Chem. 2012;19:5705–25.CrossRefPubMed Qin JJ, Nag S, Voruganti S, Wang W, Zhang R. Natural product mdm2 inhibitors: anticancer activity and mechanisms of action. Curr Med Chem. 2012;19:5705–25.CrossRefPubMed
7.
Zurück zum Zitat Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the mdm2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591–602.CrossRefPubMed Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the mdm2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591–602.CrossRefPubMed
8.
9.
Zurück zum Zitat Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
10.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMed DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMed
12.
Zurück zum Zitat Munafo MR, Clark TG, Flint J. Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Res. 2004;129:39–44.CrossRefPubMed Munafo MR, Clark TG, Flint J. Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Res. 2004;129:39–44.CrossRefPubMed
14.
Zurück zum Zitat Anton M, Horky M, Blaha O. The role of tumour suppressors and viral oncoproteins in cervical carcinogenesis. Ceska gynekologie/Ceska lekarska spolecnost. J Ev Purkyne. 2000;65:275–8. Anton M, Horky M, Blaha O. The role of tumour suppressors and viral oncoproteins in cervical carcinogenesis. Ceska gynekologie/Ceska lekarska spolecnost. J Ev Purkyne. 2000;65:275–8.
15.
Zurück zum Zitat Nunobiki O, Ueda M, Yamamoto M, Toji E, Sato N, Izuma S, et al. Mdm2 SNP 309 human papillomavirus infection in cervical carcinogenesis. Gynecol Oncol. 2010;118:258–61.CrossRefPubMed Nunobiki O, Ueda M, Yamamoto M, Toji E, Sato N, Izuma S, et al. Mdm2 SNP 309 human papillomavirus infection in cervical carcinogenesis. Gynecol Oncol. 2010;118:258–61.CrossRefPubMed
16.
Zurück zum Zitat Nunobiki O, Ueda M, Toji E, Yamamoto M, Akashi K, Sato N, et al. Genetic polymorphism of cancer susceptibility genes and HPV infection in cervical carcinogenesis. Pathol Res Int. 2011;2011:364069.CrossRef Nunobiki O, Ueda M, Toji E, Yamamoto M, Akashi K, Sato N, et al. Genetic polymorphism of cancer susceptibility genes and HPV infection in cervical carcinogenesis. Pathol Res Int. 2011;2011:364069.CrossRef
17.
Zurück zum Zitat Hu X, Zhang Z, Ma D, Huettner PC, Massad LS, Nguyen L, et al. Tp53, mdm2, nqo1, and susceptibility to cervical cancer. Cancer Epidemiol Biomarkers Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2010;19:755–61.CrossRef Hu X, Zhang Z, Ma D, Huettner PC, Massad LS, Nguyen L, et al. Tp53, mdm2, nqo1, and susceptibility to cervical cancer. Cancer Epidemiol Biomarkers Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2010;19:755–61.CrossRef
18.
Zurück zum Zitat Meissner Rde V, Barbosa RN, Fernandes JV, Galvao TM, Galvao AF, Oliveira GH. No association between snp309 promoter polymorphism in the mdm2 and cervical cancer in a study from northeastern Brazil. Cancer Detect Prev. 2007;31:371–4.CrossRefPubMed Meissner Rde V, Barbosa RN, Fernandes JV, Galvao TM, Galvao AF, Oliveira GH. No association between snp309 promoter polymorphism in the mdm2 and cervical cancer in a study from northeastern Brazil. Cancer Detect Prev. 2007;31:371–4.CrossRefPubMed
19.
Zurück zum Zitat Ueda M, Yamamoto M, Nunobiki O, Toji E, Sato N, Izuma S, et al. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum Cell. 2009;22:49–54.CrossRefPubMed Ueda M, Yamamoto M, Nunobiki O, Toji E, Sato N, Izuma S, et al. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum Cell. 2009;22:49–54.CrossRefPubMed
20.
Zurück zum Zitat Jiang P, Liu J, Li W, Zeng X, Tang J. Correlation between mdm2 gene snp309 polymorphisms and cervical cancer. Chin J Clin Oncol. 2011;38:1–4. Jiang P, Liu J, Li W, Zeng X, Tang J. Correlation between mdm2 gene snp309 polymorphisms and cervical cancer. Chin J Clin Oncol. 2011;38:1–4.
21.
Zurück zum Zitat Singhal P, Hussain S, Thakur N, Batra S, Salhan S, Bhambani S, et al. Association of mdm2 and p53 polymorphisms with the advancement of cervical carcinoma. DNA Cell Biol. 2013;32:19–27.CrossRefPubMed Singhal P, Hussain S, Thakur N, Batra S, Salhan S, Bhambani S, et al. Association of mdm2 and p53 polymorphisms with the advancement of cervical carcinoma. DNA Cell Biol. 2013;32:19–27.CrossRefPubMed
22.
Zurück zum Zitat Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;8:15–7. Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;8:15–7.
23.
Zurück zum Zitat Fu Q, Zhang G, Chen H, Zheng Y, Cheng J. Current evidence on the relationship between snp309 polymorphism in the mdm2 gene and colorectal cancer risk. Tumour Biol J Int Soc Oncodev Biol Med. 2013;34:3721–9.CrossRef Fu Q, Zhang G, Chen H, Zheng Y, Cheng J. Current evidence on the relationship between snp309 polymorphism in the mdm2 gene and colorectal cancer risk. Tumour Biol J Int Soc Oncodev Biol Med. 2013;34:3721–9.CrossRef
24.
Zurück zum Zitat Ma YY, Guan TP, Yao HB, Yu S, Chen LG, Xia YJ, et al. The mdm2 309t>g polymorphism and ovarian cancer risk: a meta-analysis of 1534 cases and 2211 controls. PLoS One. 2013;8:e55019.PubMedCentralCrossRefPubMed Ma YY, Guan TP, Yao HB, Yu S, Chen LG, Xia YJ, et al. The mdm2 309t>g polymorphism and ovarian cancer risk: a meta-analysis of 1534 cases and 2211 controls. PLoS One. 2013;8:e55019.PubMedCentralCrossRefPubMed
25.
Zurück zum Zitat Chen T, Yi SH, Liu XY, Liu ZG. Meta-analysis of associations between the mdm2-t309g polymorphism and prostate cancer risk. Asian Pac J Cancer Prev: APJCP. 2012;13:4327–30.CrossRefPubMed Chen T, Yi SH, Liu XY, Liu ZG. Meta-analysis of associations between the mdm2-t309g polymorphism and prostate cancer risk. Asian Pac J Cancer Prev: APJCP. 2012;13:4327–30.CrossRefPubMed
26.
Zurück zum Zitat Zhuo W, Zhang L, Ling J, Zhu B, Chen Z. Mdm2 snp309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects. Leuk Lymphoma. 2012;53:2245–52.CrossRefPubMed Zhuo W, Zhang L, Ling J, Zhu B, Chen Z. Mdm2 snp309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects. Leuk Lymphoma. 2012;53:2245–52.CrossRefPubMed
Metadaten
Titel
MDM2 SNP309 variation increases cervical cancer risk among Asians
verfasst von
Xianlu Zhuo
Jie Ren
Dairong Li
Yongzhong Wu
Qi Zhou
Publikationsdatum
01.06.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1695-5

Weitere Artikel der Ausgabe 6/2014

Tumor Biology 6/2014 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.